

Comparative Study on Pulmonary Function Tests in Smokers and Nonsmokers

Munna Kumar Saw¹, Vishwajit Kumar², Bijay Krishna Prasad

¹JR-3, Department of Physiology, Anugrah Narayan Magadh Medical College and Hospital, Gaya, Bihar

²Tutor, Department of Physiology, Anugrah Narayan Magadh Medical College and Hospital, Gaya, Bihar

³Professor and Head of Department, Department of Physiology, Anugrah Narayan Magadh Medical College and Hospital, Gaya, Bihar

Received: 27-12-2023 / Revised: 13-01-2024 / Accepted: 20-02-2024

Corresponding Author: Dr. Vishwajit Kumar

Conflict of interest: Nil

Abstract:

Background: Compared to non-smokers, smokers have a higher risk of developing chronic obstructive pulmonary disease (COPD). The conditions known as chronic obstructive pulmonary diseases (COPD) include emphysema, bronchial asthma, and chronic bronchitis. A standard approach for evaluating and tracking illnesses is the pulmonary function test. The purpose of this is to estimate the pulmonary function tests, such as the Peak Expiratory Flow Rate (PEFR), Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1), and the ratio of FEV1 to FVC in smokers and non-smokers. Additionally to investigate how these individuals' lung function is affected by their age and body mass index (BMI).

Methods: This cross-sectional study was carried out from July 2022 to December 2022 at ANMCH in Gaya, Bihar. A total of 121 participants were chosen, 60 of whom were smokers and 61 of whom were not. Tests for spirometry were used to evaluate lung function.

Result: It was discovered that smokers' mean FVC, FEV1, and PEFR were lower than those of non-smokers. The mean spirometric values of smokers and non-smokers differed significantly.

Conclusion: Spirometry is helpful in the early detection of abnormalities in persons who do not smoke or who smoke but are asymptomatic. PFTs should be carried out as soon as possible in smokers in order to identify reduced lung capacities and airflow restrictions.

Keywords: Smokers, Non-smokers, pulmonary function test, spirometry.

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Introduction

According to the World Health Organization (WHO), smoking caused the deaths of 100 million people globally in the 20th century and warned that it may cause the deaths of one billion people in the 21st. [1] The number of tobacco-related deaths annually would rise to almost 10 million by the early 2030s. Smoking is a common practice in India, whether one smokes cigarettes, bidis, pipes, cigars, hookahs, or anything else. It is observed in both urban and rural areas.

One of the biggest risk factors for a wide range of cardiovascular and respiratory conditions is still tobacco use. [2] Lung cancer can result from the 400 compounds in tobacco smoke, 60 of which are recognized carcinogens. Pulmonary function tests rapidly diminish when a smoker (PFTs).

The single biggest risk factor that contributes to the development of COPD is smoking. One of the main causes of morbidity and death among long-term tobacco users is chronic obstructive pulmonary

disease, or COPD. Small airways in COPD have a diameter of less than 2 mm. The indices of pulmonary function are inevitably impacted by these blockages in the airways. For instance, forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC). Cigarette smokers often experience a significant annual rate of reduction in FEV1 of approximately 50 ml, which is nearly twice the average value of 30 ml observed in nonsmokers annually. [3]

Testing one's pulmonary function is a standard practice for diagnosing and tracking respiratory conditions. Additionally helpful are the tests' lower costs, noninvasive nature, reproducibility, and little uncomfortable effects on the participants. Spirometric measurements differ based on body size, sex, age, and height.

As a result, smoking cigarettes has a significant impact on respiratory function, which a pulmonary function test can identify. Comparing the lung

function of smokers versus non-smokers was the study's main objective.

Material and Method

From July 2022 to December 2022, a cross-sectional study was carried out in the physiology department of Anugrah Narayan Magadh Medical College in Gaya, Bihar. 121 people knowingly and freely consented in writing to take part in the study. Students and staff were chosen as subjects, and smokers and non-smokers were tested using a questionnaire. There were 61 nonsmokers and 60 smokers.

A structured questionnaire asked about smoking behaviors, including how many cigarettes a day, when it started, how long it lasted, and personal information about age, gender, and work. Measurements used in anthropometry as A conventional weighing machine was used to measure weight, a stadiometer was used to measure height, and the Quetelet index was used to compute body mass index (BMI).

The National Institutes of Health has guidelines that divide weight status into four categories: underweight (BMI 18.5), normal weight (BMI between 18.5 and 24.9), overweight (BMI between 25 and 29.9), and obese (BMI \geq 30). [4]

The individuals' pulmonary function was evaluated using a series of spirometric tests, including forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), FEV1/FVC, FVC%, and

peak expiratory flow rate (PEFR), which were conducted using a digital computerized spirometer.

Prior to conducting the spirometry, the subjects were given an explanation and demonstration of the process. A stadiometer was used to measure each subject's standing height, and a conventional weighing machine was used to get their weight when they were wearing light clothing and were barefoot. The study was carried out between 10 and 11 a.m. in the physiology department of ANMMC, Gaya, Bihar, following a modest meal. To measure and estimate the pulmonary parameters, the individual inhaled as deeply as possible and exhaled as quickly and forcefully as feasible. Every person tried three times, and the highest value for every parameter was noted. [5]

Results

Table 1 presents the mean age of 34.85 ± 12.84 years for 60 smokers and 36.21 ± 9.40 years for non-smokers. The majority of them were men. Table 3 shows that the percentage of smokers (49.58%) and non-smokers (50.41%) as well as their mean height, weight, and BMI were, respectively, 159.68 ± 6.87 , 54.13 ± 7.93 , 21.25 ± 2.82 & 163.52 ± 7.50 , 57.14 ± 7.50 , and 21.29 ± 2.43 . Additionally, for smokers and non-smokers, the mean spirometric values of FVC, FEV1, FEV1/FVC, and PEFR were 1.8 ± 0.44 , 1.66 ± 0.46 , 89.35 ± 10.63 , and 4.48 ± 1.71 & 2.93 ± 0.56 , 2.60 ± 0.48 , 84.98 ± 7.58 , and 7.06 ± 1.67 , respectively. All data were analyzed statistically.

Table 1: Characters of study subjects (121) (Mean values \pm SD)

| Variable | No. of subjects | Percentage |
|-------------|-----------------|------------|
| Age (years) | <20 | 12 |
| | 20-29 | 27 |
| | 30-39 | 29 |
| | 40-60 | 53 |
| Smokers | 60 | 49.58% |
| Non-smokers | 61 | 50.41% |

BMI for underweight, normal weight, and overweight is displayed in Table 2, along with their respective percentages, numbers, and spirometric characteristics for the smokers and non-smokers groups.

Table 2: BMI Concerning

| BMI | | | FVC | FEV ₁ | FEV ₁ /FVC | PEFR |
|----------------------|----|--------|-----------------|------------------|-----------------------|-----------------|
| Underweight <18.5 | 22 | 18.18% | 2.37 ± 0.72 | 2.37 ± 0.64 | 94.35 ± 6.06 | 6.00 ± 1.86 |
| Normal – 18.5-24.9 | 90 | 74.38% | 2.39 ± 0.76 | 2.07 ± 0.68 | 88.63 ± 9.10 | 5.58 ± 2.11 |
| Overweight – 25-29.9 | 9 | 7.43% | 2.11 ± 0.16 | 2.36 ± 0.44 | 88.72 ± 6.24 | 6.40 ± 2.44 |
| Obesity \geq 30 | 0 | | | | | |

Table 3 demonstrates that there is a statistically significant difference in the mean spirometric values of FVC, FEV1, FEV1/FVC, and PEFR between smokers and non-smokers, and those non-smokers have higher mean spirometric parameters like FVC, FEV1, and PEFR than smokers. Spirometric analysis yielded a significant result ($P < 0.05$).

Table 3: Statistical difference between mean spirometric values FVC, FEV1, FEV1/FVC and PEFr between smokers and non-smokers

| Variables | Smokers (Mean±SD) | Non-Smokers (Mean±SD) | P-value |
|-----------|-------------------|-----------------------|---------|
| FVC(L) | 1.8±0.44 | 2.93±0.56 | <0.05 |
| FEV1(L) | 1.66±0.46 | 2.60±0.48 | <0.05 |
| FEV1/FVC% | 84.98±7.58 | 89.35±10.63 | <0.05 |
| PEFR(L) | 4.48±1.71 | 7.06±1.67 | <0.05 |
| BMI | 21.25±2.82 | 21.29±2.43 | |
| Height | 159.68±6.87 | 163.52±7.50 | |
| Weight | 54.13±7.93 | 57.14±7.50 | |
| Age | 34.85±12.84 | 36.21±9.40 | |

Discussion

The number of smokers is continuously rising around the world despite widespread media coverage of the negative effects of tobacco, laws and policies designed to discourage smoking, and copious amounts of research highlighting the health risks associated with second-hand smoke (SHS) exposure among adults who do not smoke. [6,7,8] Smoking cigarettes causes inflammatory alterations in the small airways, particularly the respiratory bronchioles. Emphysema is the resultant dilation and destruction of small airways. [9] Smoking-related lung damage develops gradually and may not cause symptoms until lung functions are impaired.[10]

Adolescent smokers and those exposed to second-hand smoke have lower lung function measures, and both groups are more likely to experience respiratory issues such as coughing, phlegm, asthma, and wheezing. [11,12]

As a component of PFTs, spirometry is a crucial technique for examining and tracking overall respiratory health. Spirometric tests are helpful in determining the degree of airway obstruction as well as in determining how well the pulmonary system is functioning and analyzing the effects of different treatment plans. As the highest level of lung function attained in early adulthood, FEV1 is determined at any given time in adulthood by three factors: smoking, the rate at which lung function declines, and the beginning of the decline in lung function. Cigarette smoking has an impact on all three of these factors. When a person ages and accumulates more pack years of smoking, the effects of smoking on lung function become more noticeable. The greatest FEV1 reduction is observed in current smokers. It is lowest in nonsmokers and moderate in ex-smokers. [13]

In Abhishek Biswas study, smokers' FVC and FEV1 levels were lower than those of non-smokers'. [14] In a research between smokers and nonsmokers in a rural region, Rubeena et al. found that smokers with low to moderate nicotine dependency had lower PFT levels. [15] Similar results were observed in this investigation. According to Vaidya et al. [16], ex-smokers had PFT values that were lower than those

of non-smokers but still better than those of smokers, indicating a lower pulmonary function parameter in smokers compared to nonsmokers. Compared to non-smokers, cigarette smokers had a higher annual rate of decline in FEV1, a higher incidence of respiratory symptoms and anomalies in lung function, and a higher death rate from COPD. [17]

Quitting smoking decreases the forced expiratory volume fall in a single second, suggesting a favorable impact on significant inflammatory and/or re-modelling processes. [18] In order to keep smokers' pulmonary function from further declining, quitting should be promoted.

Conclusion

Significant harm is done to the pulmonary functioning by cigarette smoking. Smokers have negative effects on almost all lung function indices long before COPD and other smoking-related problems manifest. In order to promote quitting smoking and reduce morbidity, adult smokers should have specific pulmonary functions performed on them.

References

1. Science Daily. WHO report: Tobacco could kill one billion by 2100; 2008.
2. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress: A Report of the Surgeon General. Atlanta: US Department of Health and Human Services, Centres for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health 2014(accessed 2017 Apr.20).
3. Dhand R, Malik SK, Sharma PK. Long term effects of tobacco smoking: Results of spirometric study in 300 old men. Indian J Chest Dis Allied Sci. 1985; 27:44–9.
4. World Health Organization. The Asia Pacific Perspective. Redefining obesity and its treatment. http://www.wpro.who.int/pdf/obesity_final.pdf 2000.

5. Standardization of spirometry 1994 update. American Thoracic Society. *Am J Respir Crit Care Med* 1995; 152: 1107- 36.
6. C. D. Delnevo, "Smokers' choice: what explains the steady growth of cigar use in the U.S.?" *Public Health Reports*, vol. 121, no. 2, pp. 116–119, 2006.
7. S. P. Ghataliya, K. Pipaliya, and C. Shah, "Effect of smoking on lung volume and capacity," *Southeast Asian Journal of Case Report and Review*, vol. 3, no. 2, article 8, 2014.
8. Tantisuwat and P. Thaveeratitham, "Effects of smoking on chest expansion, lung function, and respiratory muscle strength of youths," *Journal of Physical Therapy Science*, vol. 26, no. 2, pp. 167–170, 2014.
9. Diane R G, Xiaobin W, David W, Frank E S, James H W et al., Effects of Cigarette smoking on lung function in adolescent boys and girls; *The New England Journal of Medicine*, September 1996, 335: 13; 931-937.
10. Down HS, Brandil O, Zellweger JP, et al., Accelerated decline in lung function in smoking women with airway obstruction: SAPALDIA 2 cohort study; *Respiratory Research*, May 2005, 6: 45
11. Y. Liu, R.A. Pleasants, J.B. Croft, A. G. Wheaton, K. Heidari, A. M. Malarcher et al..., "Smoking duration, respiratory symptoms, and COPD in adults aged \geq 45 years with a smoking history," *International Journal of Chronic Obstructive Pulmonary Disease*, vol. 10, pp. 1409–1416, 2015.
12. S. Stoleski, J. Minov, D. Mijakoski, and J. Karadzinska- Bislimovska, "Chronic respiratory symptoms and lung function in agricultural workers - Influence of exposure duration and smoking," *Macedonian Journal of Medical Sciences*, vol. 3, no.1, pp. 158–165, 2015.
13. Giovino GA, Mirza SA, Samet JM, et al., for the GATS Collaborative Group. Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys. *Lancet* 2012; 380: 668–879.
14. Abhishek Ghosh Biswas and Dheeraj Khatri, Pulmonary function tests among the students of Sikkim Manipal institute of medical sciences, Gangtok. *International Journal of Advanced Research* 2017, 5(9), 336-341.
15. RubeenaBano, Mahagaonkar AM, Kulkarni NB, Nadeem Ahmad, Nighute; Study of Pulmonary Function Tests among Smokers and Non-Smokers in a Rural Area; 2009;4(1);11-16.
16. Vaidya P, Kashyap S, Sharma A, Gupta D, Mohapatra PR, Respiratory symptoms and pulmonary function test in schoolteachers of Shimla; *Lung India* 2007, 24: 6-10.
17. Geijer RM, Sachs AP, Hoes AW, Salome PL, Lammers JW, Verheij TJ. Prevalence of undetected persistent airflow obstruction in male smokers 40-65 years old. *FamPract.* 2005; 22:485–9.
18. Willemse BW, Postma DS, Timens W, Hacken NH. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. *EurRespir J.* 2004; 23:464-76.